July 5, 2023 | Berlin, Germany and Peynier, France
Eckert & Ziegler (ISIN DE0005659700, TecDAX), via its subsidiaries Eckert & Ziegler Eurotope GmbH (ETD) and PentixaPharm GmbH (PentixaPharm), and PMB Alcen (PMB), a French technology company focusing on solutions for radionuclide and radiopharmaceutical production, today announced the signing of a Letter of Intent (LoI) to collaborate on an advanced solution for the synthesis of radiotherapeutic agents.
The three companies will combine their expertise in different fields to jointly develop and commercialize a robust, GMP-compliant solution for the scalable synthesis of radiotherapeutic agents. Following promising results obtained using iMiDEV’s microfluidic technology, the partnership aims to address the growing demand for advanced radiopharmaceuticals used in the treatment of various types of cancers, initially focusing on PentixaPharm’s Yttrium-90 based agents targeting the CXCR4-receptor.
“We are excited to partner with Eckert & Ziegler to develop a cutting-edge solution for the scalable synthesis of radiotherapeutic agents”, stated Dr. Nicolas Massé, Nuclear Medicine Business Unit Director of PMB Alcen. “PMB will contribute our long-term experience in medical sub-systems, microfluidic radiopharmaceutical synthesizers, and particle accelerators to this project. Together, we aim to revolutionize the field of radiopharmaceutical production and bring innovative treatment options to patients worldwide.”
“This collaboration represents a major milestone in our ongoing efforts to provide advanced solutions for the development and production of radiopharmaceutical substances” added Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH. “Combining Eurotope’s expertise in radiosynthesis and quality control devices with the know how of these two innovators will push the availability of GMP-compliant radiopharmaceuticals to the next level.”
“PentixaPharm is committed to improve patient care by developing innovative theranostic agents for various life-threatening diseases,” stated Dr. Jens Kaufmann, Managing Director of PentixaPharm GmbH. “This collaboration tackles a major challenge to reach this goal – reliable and sufficient access to our products on the manufacturing side. We are therefore pleased to contribute our technology to this pilot project and jointly pave the way for industrial scale manufacturing for the future global demand of radiopharmaceuticals.”
The partnership between PMB, ETD and PentixaPharm reinforces the commitment of all three companies to advancing the field of radiopharmaceuticals. It will significantly enhance the efficiency of radiopharmaceutical manufacturing, ensuring a reliable supply of radiopharmaceuticals to hospitals and research institutes by CMOs and pharmaceutical companies.
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Eckert & Ziegler Eurotope
Eurotope GmbH belongs to the Eckert & Ziegler group and represents the Lab Devices business unit of the Medical Segment. The company develops, manufactures and sells systems and accessories for radionuclide labeling and quality control of radiopharmaceuticals. The products are used in research and routine manufacturing of patient doses for cancer diagnosis and therapy in hospitals, as well as in industrial manufacturing processes for radioactively labeled compounds and drugs.
As part of the Medical Segment, Eurotope GmbH contributes to provide complete solutions to Eckert & Ziegler’s worldwide customers in the nuclear medicine and pharma industry. The comprehensive product and service portfolio of Medical’s One-Stop-Shop ranges from customized hot cell solutions and in-cell equipment over radionuclides to contract development and GMP-manufacturing services for radiopharmaceuticals through all stages from early clinical to commercial supply.
PentixaPharm is developing the innovative theranostic pair PentixaFor and PentixaTher. These two peptide-based radiopharmaceuticals specifically target the CXCR4-receptor, which is over expressed in many hematological diseases as well as various other malignant indications. The aim is to develop a specific diagnostic PET tracer linked to Gallium-68, called PentixaFor for accurate identification and localization of CXCR4 overexpressing tumors. The therapeutic agent PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90) with the potential to precisely destroy the targeted lesions. Both products are currently under clinical development.
About PMB Alcen
PMB is a human-sized company located near Aix-en-Provence, in the south of France, specialized in the design and manufacture of complex particle accelerators systems for Medical, Research, Nuclear, Defense and Industry applications.
Historically, PMB started with the specialty of assembling dissimilar materials such as metals and ceramics. Since 2010, PMB develops complex systems integrating particle accelerators. Among others, an automated system that produces in-house PET radiopharmaceuticals and linear accelerators for non-destructive testing (high-energy radiography), and radiotherapy. PMB is part of the French industrial group ALCEN.